All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport ® ) are Alkemist Assured LOS ANGELES / Mar 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces that its flagship Tru Niagen ®... Read More

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. LOS ANGELES / Mar 06, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023... Read More

LOS ANGELES / Feb 21, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market... Read More

LOS ANGELES / Jan 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings... Read More

Tru Niagen is now available to US troops through an exclusive Military program LOS ANGELES / Dec 20, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. As the most efficient, studied, and high-quality NAD+ boosting supplement on the market, ChromaDex’s... Read More

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. SAN DIEGO , Dec. 12, 2023 /PRNewswire/ -- Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since... Read More

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day LOS ANGELES / Nov 30, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares results from a... Read More

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated LOS ANGELES / Nov 15, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares... Read More

LOS ANGELES / Nov 09, 2023 / Business Wire / ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders,... Read More

Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. LOS ANGELES / Nov 08, 2023 / Business Wire / ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sales... Read More

Tru Niagen ® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD + levels by up to 150% in as little as three weeks LOS ANGELES / Nov 01, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and... Read More

LOS ANGELES / Oct 31, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023. The financial results will be reported in a press release after the close of regular stock market... Read More

The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws ® , debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Niagen ® LOS ANGELES / Oct 26, 2023 / Business Wire /... Read More

Celebrating a significant achievement in NAD + research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders LOS ANGELES / Oct 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy aging,... Read More

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES / Aug 24, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy... Read More

Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. LOS ANGELES / Aug 09, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023. Second Quarter 2023 and Recent Highlights... Read More

This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. LOS ANGELES / Aug 08, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.... Read More

Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16 LOS ANGELES / Aug 07, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation... Read More

LOS ANGELES / Aug 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the... Read More

Abstracts recently published in the Association for Research in Vision and Ophthalmology (ARVO) journal showcase NR, one of the most efficient and well-researched NAD+ precursors, prevented the worsening of visual field sensitivity in glaucoma patients, and builds on research demonstrating decreased cellular NAD+ levels and impaired mitochondrial function are associated with Primary open-angle glaucoma (POAG) LOS ANGELES /... Read More

Through CERP™, over 275 global research agreements with 235+ independent, expert investigators are uncovering the full potential of NAD+ by researching ChromaDex’s Niagen® ingredient, patented nicotinamide riboside (NR), one of the most studied and efficient modern NAD+ precursors in the healthy aging space, among other ingredients LOS ANGELES / Jun 16, 2023 / Business Wire / On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a... Read More

LOS ANGELES / May 30, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings. ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer,... Read More

LOS ANGELES / May 11, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday,... Read More

Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023. LOS ANGELES / May 10, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023. First Quarter 2023 and Recent Highlights Total net... Read More

LOS ANGELES / May 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading... Read More

Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 and Recent Highlights Total net sales were $21.0... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The Annual ROTH Conference is one of the largest in the nation for small-cap companies and combines company presentations, Q&A sessions and management 1-on-1 meetings. The... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year, which ended December 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as... Read More

Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and related derivatives, some of the most... Read More

The following is issued on behalf of ChromaDex (NASDAQ: CDXC). Dear Fellow Shareholders: I want to take this opportunity to provide an update on ChromaDex’s intellectual property portfolio, as well as perspective on why our business is not impacted by a recent court decision related to one of the Dartmouth patents slated to expire in 2026. Last week we learned that the U.S. Court of Appeals for the Federal Circuit affirmed a... Read More

This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers ChromaDex Corp . (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil... Read More

NR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led... Read More

Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative... Read More

ChromaDex Corp . (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex since August 11, 2022, and prior to that was the Vice President of Finance and Investor Relations of ChromaDex since September 17,... Read More

Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging ChromaDex Corp . (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen ® ingredient (patented nicotinamide riboside or... Read More

U.S. FDA declares NMN ingredient may not be sold or marketed as a dietary supplement in the U.S. since first investigated as a drug ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mononucleotide (NMN) may no longer be sold or marketed as a dietary supplement in the United States since it was first investigated... Read More

Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, for the three months ended September 30, 2022. ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022. Third Quarter 2022 and Recent Highlights Total net sales were $17.1 million, with $14.6 million from Tru... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the... Read More

Tru Niagen ® was recognized for its industry-leading research, increased presence on cross-border e-commerce channels, and high engagement on several social media platforms in Mainland China ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that its consumer nicotinamide adenine dinucleotide (NAD + ) boosting supplement, Tru Niagen ® , won the “Most Popular Brand of the Year... Read More

The new agreement extends non-exclusive rights to sell Niagen ® in multi-ingredient dietary supplements The agreement includes an initial Niagen ® ingredient purchase commitment of $1.975 million in 2022 ChromaDex will be eligible to receive commercial milestone payments, as well as tiered royalties, related to the sale of Nestlé’s Niagen ® containing products ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a... Read More

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a team of... Read More

ChromaDex Corp. (NASDAQ:CDXC) (the “Company”), a global bioscience company dedicated to healthy aging, today announced that it has established a joint venture through its wholly owned subsidiary ChromaDex Asia Pacific Ventures Limited (the “JV” or “ChromaDex Asia”). The JV collectively consists of the Company and Hong Kong Taikuk (China) Group Limited. The purpose of the JV will be to commercialize Tru Niagen® and other... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen ® at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia’s largest expo on natural health and nutrition products, with over 100,000 distributors and retailers. It is considered the best platform to help global manufacturers of... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen ® and Tru Niagen ® PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen ® , is the world’s most efficient nicotinamide adenine dinucleotide (NAD + ) precursor on the market, particularly over NMN (nicotinamide mononucleotide).... Read More

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s (“PTAB”) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (“the 807 patent”). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Highlights Total net sales were $16.7 million, with $14.5 million from Tru Niagen®, down 5% and 6% from the prior year period, respectively. Total net sales and Tru Niagen® net sales remained relatively flat year over year excluding the initial shelf stocking sales to Wal-Mart in the second quarter... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time. The webinar will feature a presentation from KOL and discoverer of the vitamin activity of NR, Dr. Charles Brenner, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition’s (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen ® into mainland China. Tru Niagen ® features ChromaDex’s proprietary Niagen ® (patented nicotinamide... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22 nd Annual Consumer Growth and E-Commerce Conference. The ChromaDex management team is scheduled to present virtually on Wednesday, June 15 th at 3:45 p.m. Eastern Time (12:45 p.m. Pacific Time). ChromaDex management will also attend virtual one-on-one... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen ® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. With strong partnerships in a dynamic and trend-setting Korean market, Juvenis emphasizes products with differentiated science and proven benefits. Tru Niagen ® is one of Amazon’s... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12 th annual Invitational. This three-day investor conference is expected to feature around 200+ companies. The ChromaDex management team is scheduled to present on Wednesday, June 8 th at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) at the Four Seasons... Read More

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the “JV” or “ChromaDex Asia”). Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the Company; Crystal Lake Developments Limited;... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients , a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP TM ) with a 2022 European NutraIngredients Award in the “Nutrition Research Project” category for developing the science behind ChromaDex’s... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022. First Quarter 2022 and Recent Highlights Total net sales were $17.3 million, up 18% from the prior year quarter. Tru Niagen® net sales were $14.9 million, a 20% increase from the prior year quarter. In April 2022, the ChromaDex External Research Program (CERP) achieved its 250th material transfer agreement since 2013, resulting in... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call ChromaDex management will host an investor... Read More

ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (The IIA). “We welcome Ms. Patrick and Ms. Cohen to our distinguished ChromaDex Board of Directors,” said Rob Fried, CEO... Read More

ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program ( CERP ™), featuring ChromaDex’s flagship ingredient Niagen ® (patented nicotinamide riboside, or NR) and other proprietary ingredients. Over 235 independent scientists, doctors, and... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced the company’s latest product innovation with the U.S. launch of Tru Niagen ® Immune , a first-of-its-kind combination of ChromaDex’s proprietary NAD-boosting ingredient Niagen ® (patented nicotinamide riboside or NR), high-quality and proven immune-boosting nutrients (vitamins C,... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117 , adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. This newly granted continuation patent reinforces U.S. Patent No. 11,242,364 , which was just granted to ChromaDex on February 8, 2022 (full press release here... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results. Fourth Quarter 2021 and Recent Highlights Total net sales were $17.8 million, up 15% year over year. Tru Niagen® net sales were $14.1 million, a 14% increase year over year. Gross margin was 61.2%, up 20 basis points year over year. Net loss was $5.3 million or $0.08 loss per share, an improvement of $0.02 per share year over... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen, in Norway. The clinical trial was part of the ChromaDex External Research Program (CERP™) and investigated the company’s proprietary Niagen® ingredient... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation . The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen ® , the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021. Third Quarter 2021 and Recent Highlights Total net sales were $17.3 million, up 22% from the prior year quarter. Tru Niagen® net sales were $14.8 million, a 24% increase from the prior year quarter. Gross margin was 61.1%, a 150 basis point increase from the prior year quarter. Net loss was $(8.9) million or $(0.13) per share, a... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders , conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex’s proprietary Niagen ® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call ChromaDex management will host an investor conference... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Health, Inc. (“Elysium”) breached its contract with ChromaDex by failing to pay for product it ordered and received in 2016. Based on the jury’s verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated... Read More

ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. It is the main platform of... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or “NR”) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NR’s... Read More

ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. (“Elysium”) in the United States District Court for the District of Delaware. ChromaDex licenses U.S. Patent No. 8,383,086 (“the ’086 patent”) and U.S. Patent No. 8,197,807 (“the ’807... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021. Second Quarter 2021 and Recent Highlights Total net sales were $17.7 million, up 16% from the prior year quarter. Tru Niagen® net sales were $15.4 million, a 31% increase from the prior year quarter. Gross margin was 61.1%, a 170 basis point increase from the prior year quarter. Net loss was $(5.6) million or $(0.08) per share,... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference... Read More

ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex provides its patented NR ingredient, Niagen®, technological and scientific expertise to research institutions and universities at no cost.... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across the United States. Walmart is the first major U.S. retailer to bring this well-studied healthy aging nutrient to stores. “We are grateful to Walmart for their commitment to the Tru... Read More

ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 million, up 2% from $14.3 million in the year ago quarter. Tru Niagen® net sales of $12.4 million, a 12% increase from the year ago quarter. Gross margin of 62.9%, a 500 basis point increase from the year ago quarter. Net loss was ($7.4) million or ($0.12) per share, down $0.02... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for specially formulated Roman products. “Ro has made great strides in a short period of time and we are looking forward to working... Read More

ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET (8:30am PT). ChromaDex CEO, Rob Fried, will also be presenting on a panel in the Transformative Healthcare track, entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.” The panel is scheduled for Thursday, May 13,... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call... Read More

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations across digital, social, and traditional marketing platforms, as well as launching and scaling product innovation. Prior to joining ChromaDex, Karam led the local brand... Read More

ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential... Read More